Seagen, new modalities & newco Structure: a BioCentury podcast
How Seagen has built an ADC pipeline around almost entirely first-in-class targets, plus emerging company Structure Therapeutics
By Jeff Cranmer, Executive Editor
August 2, 2022 12:52 AM UTC
Acquisition target Seagen Inc. (NASDAQ:SGEN) has carved out such a differentiated portfolio of antibody-drug candidates that the company may not see much direct competition from other ADCs in the near term, BioCentury’s Lauren Martz says on the latest edition of the BioCentury This Week podcast. Martz and the BioCentury podcast team analyze how Seagen has built a pipeline around almost entirely first-in-class targets and assess how the latest cut of data for the company’s Padcev enfortumab vedotin-ejfv could broaden the ADC’s reach among cancer patients.
BioCentury’s editors also discuss cross-border start-up Structure Therapeutics Inc.’s mission to make biologics more accessible on a global scale. The newco, which is led by Raymond Stevens, has raised nearly $200 million from a broad syndicate of investors to support its small molecule GPCR platform.
This week’s podcast was sponsored by the BioCentury-BayHelix East-West Summit 2022, a gathering of biopharma executives and investors focused on building trusted cross-border relationships across the biopharma ecosystem. The VIP event takes place in the San Francisco Bay Area Nov. 14-16.For information on how to sponsor BioCentury This Week and The BioCentury Show, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.
